शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

SYSCHEM (INDIA) LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹31.58
at close · 6 Nov 2026
▼ 0.52 (-1.62%)

Latest filings

  1. September 2026 results: flat quarterly profit, half-year profit down 93% · Results
  2. Newspaper publication of September 2026 quarterly results · Compliance
  3. Q2 FY26-27 profit rebounds as revenue and operating earnings improve · Investor Communications
All filings ↓
Ask Nexa about SYSCHEM (INDIA) LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹666 Cr over the trailing twelve months.

Market Cap
₹169 Cr
P / E (TTM)
22.4×
EV / EBITDA
8.3×
Div Yield
—
Growth
54.5%▲
Revenue 5y CAGR
PAT — · EBITDA —
Quality
6.5%·
ROCE (5y median)
ROE 3.6% (5y median) · margin 3.2%
Leverage
0.00·
Debt / Equity · low
Net cash ₹0.76 Cr
Revenue FY21→FY26
8.8×▲
Margin +9.1 pts
₹74 Cr → ₹655 Cr
Cash conversion
-2.19×▼
Operating cash ÷ profit · 5 yrs
₹-36 Cr on ₹16 Cr
Moves on a normal day
1.61%·
Median daily move
Last 268 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#57/160
P/B#31/163
ROCE#146/177
ROE#143/165
Debt / Equity#43/166
EBITDA margin#140/178
Revenue growth#99/163
Profit growth#98/157

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Revenue compounding 55% a year over 5 years
Debt at 0.00× equity
lower than 75% of its 166 Pharmaceuticals peers
Concerns
Returns on capital 6.5% (5-year median)
#146 of 177 in Pharmaceuticals on the latest reported figures · up from −20.0% in FY21
Over 5 years it reported ₹16 Cr of profit and an operating cash outflow of ₹36 Cr — -2.19×
Less than 60p of every ₹1 of profit arrived as cash
Customers are taking longer to pay — 28 → 81 days of receivables
FY21 → FY26

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from SYSCHEM (INDIA) LTD.'s filed financials and exchange disclosures

What does SYSCHEM (INDIA) LTD. do?

SYSCHEM (INDIA) LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.

Is SYSCHEM (INDIA) LTD. profitable?

Yes. Over the trailing twelve months SYSCHEM (INDIA) LTD. reported a net profit of ₹6.16 Cr on revenue of ₹666 Cr.

Does SYSCHEM (INDIA) LTD. pay a dividend?

Not in the latest reported year — SYSCHEM (INDIA) LTD.'s dividend payout for FY26 was nil.

Is SYSCHEM (INDIA) LTD. debt-free?

On a net basis, yes. It reported borrowings of ₹0.87 Cr on its 30 Sept 2026 balance sheet, but holds ₹0.76 Cr more cash than debt.

Is SYSCHEM (INDIA) LTD. expensive compared with its peers?

On trailing P/E, SYSCHEM (INDIA) LTD. ranks 57 of 160 in Pharmaceuticals — cheaper than 65% of them, against an industry median of 29.3×. This is a position, not a valuation judgement.

How much does the SYSCHEM (INDIA) LTD. share price move in a day?

On a typical session SYSCHEM (INDIA) LTD. moves 1.61% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.

Where can I track SYSCHEM (INDIA) LTD.'s announcements?

Every NSE and BSE filing by SYSCHEM (INDIA) LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.